Anova Health Institute,Johannesburg,South Africa.
Mopani Department of Health,Giyani,South Africa.
Epidemiol Infect. 2018 Jan;146(2):246-255. doi: 10.1017/S0950268817002746. Epub 2017 Dec 6.
Xpert MTB/RIF (Xpert) is the preferred first-line test for all persons with tuberculosis (TB) symptoms in South Africa in line with a diagnostic algorithm. This study evaluates pre- and post-implementation trends in diagnostic practices for drug-sensitive, pulmonary TB in adults in an operational setting, following the introduction of the Xpert-based algorithm. We retrospectively analysed data from the national TB database for Greater Tzaneen sub-district, Limpopo Province. Trends in a number of cases, diagnosis and outcome and characteristics associated with death are reported. A total of 8407 cases were treated from 2008 until 2015, with annual cases registered decreasing by 31·7% over that time period (from 1251 to 855 per year). After implementation of Xpert, 69·9% of cases were diagnosed by Xpert, 29·4% clinically, 0·6% by smear microscopy and 0·1% by culture. Cases with a recorded microbiological test increased from 76·2% to 96·4%. Cases started on treatment without confirmation, but with a negative microbiological test increased from 7·1% to 25·7%. Case fatality decreased from 15·0% to 9·8%, remaining consistently higher in empirically treated groups, regardless of HIV status. Implementation of the algorithm coincided with a reduced number of TB cases treated and improved coverage of microbiological testing; however, a substantial proportion of cases continued to start treatment empirically.
Xpert MTB/RIF(Xpert)是南非所有结核病(TB)症状患者的首选一线检测方法,符合诊断算法。本研究评估了在引入基于 Xpert 的算法后,成人药物敏感性肺结核在操作环境下的诊断实践的实施前和实施后的趋势。我们回顾性分析了林波波省大滕泽恩次区域国家结核病数据库的数据。报告了一些病例、诊断和结果的趋势以及与死亡相关的特征。2008 年至 2015 年期间共治疗了 8407 例病例,在此期间,每年登记的病例数减少了 31.7%(从每年 1251 例降至 855 例)。在实施 Xpert 后,69.9%的病例通过 Xpert、29.4%的病例通过临床诊断、0.6%的病例通过涂片显微镜检查和 0.1%的病例通过培养来诊断。有记录的微生物学检测的病例数从 76.2%增加到 96.4%。开始治疗但无确认且微生物学检测为阴性的病例数从 7.1%增加到 25.7%。病死率从 15.0%降至 9.8%,但无论 HIV 状况如何,经验性治疗组的病死率始终较高。算法的实施与治疗的结核病病例数量减少和微生物学检测覆盖率提高有关;然而,仍有相当一部分病例继续经验性治疗。